The Misleading "Pooled Effect Estimate" of Crude Data from Observational Studies at Critical Risk of Bias: The Case of Tocilizumab in Coronavirus Disease 2019 (COVID-19).
作者信息
Tleyjeh Imad M
机构信息
Infectious Diseases Section, Department of Medical Specialties, King Fahad Medical City, Riyadh, Saudi Arabia.
Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
出版信息
Clin Infect Dis. 2021 Jun 15;72(12):e1154-e1155. doi: 10.1093/cid/ciaa1735.
Abstract
摘要
相似文献
1
The Misleading "Pooled Effect Estimate" of Crude Data from Observational Studies at Critical Risk of Bias: The Case of Tocilizumab in Coronavirus Disease 2019 (COVID-19).存在偏倚重大风险的观察性研究原始数据的误导性“合并效应估计值”：以托珠单抗治疗2019冠状病毒病（COVID-19）为例
Clin Infect Dis. 2021 Jun 15;72(12):e1154-e1155. doi: 10.1093/cid/ciaa1735.
2
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析，首次更新。
Clin Microbiol Infect. 2021 Aug;27(8):1076-1082. doi: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27.
3
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
4
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
5
Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.托珠单抗治疗 COVID-19 住院患者的疗效：系统评价和荟萃分析。
Respirology. 2021 Nov;26(11):1027-1040. doi: 10.1111/resp.14152. Epub 2021 Oct 3.
6
Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study.托珠单抗或糖皮质激素治疗 SARS-CoV-2 肺炎患者：一项观察性研究。
Braz J Infect Dis. 2022 Jan-Feb;26(1):101702. doi: 10.1016/j.bjid.2021.101702. Epub 2021 Dec 21.
7
Signals were broadly positive for months, but never definitive: the tocilizumab story.数月来，信号广泛向好，但一直无法明确：托珠单抗的故事。
Clin Microbiol Infect. 2022 Mar;28(3):371-374. doi: 10.1016/j.cmi.2021.10.018. Epub 2021 Nov 9.
8
Special case of a patient in the blast phase of chronic myeloid leukemia successfully treated with tocilizumab during critical SARS-CoV-2 infection.慢性髓性白血病急变期患者在严重 SARS-CoV-2 感染期间成功接受托珠单抗治疗的特殊病例。
J Int Med Res. 2022 Mar;50(3):3000605221082875. doi: 10.1177/03000605221082875.
9
Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab.接受托珠单抗治疗的2019冠状病毒病（COVID-19）患者的结局异质性
Clin Infect Dis. 2022 Apr 28;74(8):1504. doi: 10.1093/cid/ciab816.
10
Tocilizumab in Coronavirus Disease 2019: Give It Time!托珠单抗治疗冠状病毒病2019：给它一些时间！
Clin Infect Dis. 2021 Dec 16;73(12):2368-2369. doi: 10.1093/cid/ciab081.
引用本文的文献
1
Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis.高剂量静脉注射免疫球蛋白对重症 COVID-19 患者死亡率的影响：一项更新的系统评价和荟萃分析。
Front Immunol. 2023 Jan 23;14:1116738. doi: 10.3389/fimmu.2023.1116738. eCollection 2023.
Zotero 插件